Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019
Atrial fibrillation A meta-analysis of 10 RCTs involving 12,651 patients (7,285 on semaglutide [oral and subcutaneous] and 5,366 on placebo) with a median follow-up of 68 months found that semaglutide significantly reduces the risk of AF by 42% compared to placebo (RR 0.58
Ongoing Monitoring Regular check-ins to track your progress, adjust dosage, and ensure you're feeling your best
Remember that newer doesnt always mean better for everyone
We remain focused on identifying measures that balance feasibility, burden, and impact, while aligning with shifting administration priorities as the health system continues to evolve